SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing intense downward pressure as community members react to the start of a landmark multi-state trial alleging the company designed its platforms to be addictive to children. While some retail investors view the volatility and negative headlines as an opportunity to buy the dip, many are concerned that prolonged legal uncertainty and heavy capital expenditures will continue to weigh on the stocks performance.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

Klarna is facing significant downward pressure, with shares tumbling following a downward revision to its annual revenue guidance and the announced departures of key executive leadership. While some investors see the pullback as an oversold opportunity to buy into a premium fintech name, the community remains divided as sentiment shifts between long-term bullishness on growth and skepticism regarding management's ability to navigate current economic headwinds.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike stock is facing a significant sell-off as investors react to concerns over shifting consumer demand and a perceived loss of brand momentum in the competitive sportswear sector. While some traders view the decline as an oversold opportunity to initiate a long-term position, others in the community remain skeptical, focusing on ongoing debates around the companys strategic pivots and future growth potential.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology is trending as traders speculate on upcoming Q2 earnings, with investors debating whether the stock's recent volatility is a setup for a major squeeze or continued downside. The conversation is dominated by contrasting views, with bulls highlighting the potential for explosive growth driven by AI infrastructure contracts and recent institutional accumulation, while bears emphasize concerns over share dilution and the lack of a confirmed earnings release date.

Baidu, Inc. engages in the provision of internet search and online marketing solutions. The firm’s products and services include Baidu App, Baidu Search, Baidu Feed, Haokan, Quanmin, Baidu Post Bar, Baidu Knows, Baidu Encyclopedia, Baidu Input Method Editor or Baidu IME, Baidu AI Cloud and Overseas Products. It operates through the following segments: Baidu Core and iQIYI. The Baidu Core segment provides search-based, feed-based, and other online marketing services. The iQiyi segment is an online entertainment service provider, which offers original, professionally produced and partner-generated content on its platform. The company was founded by Yanhong Li and Xu Yong on January 18, 2000 and is headquartered in Beijing, China.

Baidu Inc - ADR

Baidu is currently under intense pressure following a disappointing quarterly earnings report, with the community expressing frustration over the decline of legacy advertising revenue and concerns regarding the company's AI monetization strategy. Investors are actively debating the long-term outlook, weighing the potential value of the Kunlunxin chip unit spinoff against persistent market skepticism surrounding Chinese tech ADRs.

Amylyx Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of therapies for diseases with significant unmet medical need, with an emphasis on endocrine and neurodegenerative disorders. Its program, avexitide, is a once-daily GLP-1 receptor antagonist being developed for the treatment of post-bariatric hypoglycemia. Amylyx’s pipeline also includes investigational programs targeting Wolfram syndrome and amyotrophic lateral sclerosis (ALS). The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Amylyx Pharmaceuticals Inc

Amylyx Pharmaceuticals is trending following positive topline results from its Phase 3 LUCIDITY trial, which showed a statistically significant reduction in hypoglycemic events for patients with post-bariatric hypoglycemia. The community is heavily focused on the company's clear regulatory path to an NDA filing, its strong cash position, and widespread speculation about a potential buyout or acquisition by larger pharmaceutical firms.

The Home Depot, Inc. engages in the sale of building materials and home improvement products. Its products include building materials, home improvement products, lawn and garden products and décor products. The firm operates through the following geographical segments: U.S., Canada and Mexico. It offers home improvement installation services, and tool and rental equipment. The company was founded by Bernard Marcus, Arthur M. Blank, Kenneth Gerald Langone and Pat Farrah on June 29, 1978 and is headquartered at Atlanta, GA.

Home Depot, Inc.

Home Depot is trending as investors monitor earnings results amid a challenging housing market and broader economic concerns, with the community actively debating whether the stock's recent price action represents a buying opportunity for long-term value or a sign of further downside. Traders are closely watching for updates on the pro segment and consumer demand trends, while weighing potential implications of high interest rates on home improvement projects.

Duos Technologies Group, Inc. designs, develops, deploys, and operates intelligent technology solutions supporting rail, logistics, intermodal and government customers that streamlines operations, improves safety and reduces costs. It offers imaging, safety and security, software, and services. The firm also provides cutting edge solutions that automate the mechanical and security inspection of fast moving trains, trucks and automobiles through a broad range of proprietary hardware, software, information technology and artificial intelligence. The company was founded on May 31, 1994 and is headquartered in Jacksonville, FL.

Duos Technologies Group Inc

Duos Technologies is trending as investors digest its recent earnings, which highlighted a strategic shift toward AI-powered edge data centers and high-capacity hosting agreements. Community members are actively debating the company's growth potential versus dilution risks, with many closely tracking the rapid deployment of its proprietary edge infrastructure as a solution to broader industry bottlenecks.

FuelCell Energy, Inc. is an American clean energy technology company that delivers continuous, scalable baseload power for mission-critical applications globally. It engages in the development, design, production, construction, operation, and servicing of high-temperature fuel cells for clean electric power generation. The company’s fuel cell systems generate electricity directly at the point of use, enabling reliable, low-emission power for data centers, industrial facilities, utilities, and distributed generation customers. FuelCell Energy delivers commercially proven, modular, utility-scale systems backed by global fuel cell deployments approaching one gigawatt. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending as investors weigh strong institutional accumulation and growth potential in the data center energy market against concerns over dilution and execution. The community remains focused on upcoming project milestones, particularly related to carbon capture and commercial deal flow, which remain the primary drivers for price volatility.

Investment Managers Series Trust II - Tradr 2X Short SNDK Daily ETF

Tradr 2X Short SNDK Daily ETF

The Tradr 2X Short SNDK Daily ETF (SNDQ) is experiencing high volatility as traders react to extreme price swings in SanDisk (SNDK) and intense debate over the semiconductor sector's AI-driven valuation. The community is actively discussing the stock's speculative nature and the impact of rapid price movements, with many retail traders focused on timing their entries and exits around the stock's significant volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Mirum Pharmaceuticals (MIRM) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on August 10, 2026, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 26,050 shares of common stock and 34,590...

Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View Raised

MIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.

Citizens Says FDA’s 'Unexpected' Phase 3 Request Clouds Mirum’s Near-Term Outlook – MIRM Stock Crashes 15%

Equity

The firm said the U.S. Food and Drug Administration’s request for an additional Phase 3 trial of Volixibat to treat a liver disease is expected to delay the program.


Compared to Estimates, Mirum Pharmaceuticals (MIRM) Q2 Earnings: A Look at Key Metrics

The headline numbers for Mirum Pharmaceuticals (MIRM) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Mirum Pharmaceuticals, Inc. (MIRM) Reports Q2 Loss, Beats Revenue Estimates

Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -3.90% and +6.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Mirum Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today reported financial results for the second quarter 2026 and provided a business update. Mirum delivered another strong quarter, with continued commercial momentum supporting an increase to our full-year net product...

Mirum Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 5, 2026

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that it will report second quarter 2026 financial results on August 5, 2026. Mirum will also host a conference call to discuss the second quarter 2026 financial results and recent corporate progress...

Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on July 10, 2026, the Compensation Committee of Mirums Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 6,300 shares of common stock and 9,300...

INCY Stock Hits 52-Week High on Regulatory Updates for Opzelura

Incyte shares hit a 52-week high as Opzelura gains regulatory momentum, pipeline advances and a CMS settlement boosts investor sentiment.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products pipeline includes Maralixibat, Cholbam, Ctexli, Volixibat, Brelovitug, MRM-3379, and Zilurgisertib. The company was founded by Niall O'Donnel, Michael G. Grey, and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.

Mirum Pharmaceuticals Inc

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

MIRMMirum Pharmaceuticals Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest MIRM News